ClinicalTrials.gg
WithdrawnNCT06501924Updated Nov 2, 2026

Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss

A Phase 3 interventional study of DA-005 and Topical minoxidil 5% in Androgenetic Alopecia, Female Pattern Baldness and Male Pattern Baldness, sponsored by Applied Biology, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Applied Biology, Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Sponsor change of formulation
Updated Nov 2, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Alopecia by Applied Biology, Inc. — 3 open to participants now, 3 under way, 2 of them phase 3. Alopecia · Applied Biology, Inc..

Started
2027
with 2 others
Phase 3
3 of 13
1 open now
Registered
8th of 13
by date

Among the 13 studies in Alopecia by Applied Biology, Inc., this one is one of 3 that started in 2027, is one of 3 in phase 3, and was the 8th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

3 of the 13 studies in Alopecia by Applied Biology, Inc. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Alopecia by Applied Biology, Inc., or all of them as a file.
02

Study summary

The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).

Read the detailed description

DA-005 is a botanical supplement with demonstrated HIF-1a inhibitory action. The ingredients were tested in-vitro and have demonstrated the HIF-1a inhibitory effect. The primary aim of the study is to compare DA-005 to topical minoxidil in the treatment of hair loss (also known as androgenetic alopecia).

DA-002 is a topical alpha 1 agonist. The ingredients were tested in-vitro and have demonstrated hair growth effects. The secondary aim of the study is to compare DA-002 to topical minoxidil in the treatment of hair loss (also known as androgenetic alopecia).

03

Conditions studied

  • Androgenetic Alopecia
  • Female Pattern Baldness
  • Male Pattern Baldness

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Diagnosed with androgenetic alopecia
  • Willing and able to apply the treatment as directed, comply with study
  • Otherwise healthy
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • A medical history that may interfere with study objectives
  • Women who are pregnant, lactating, or planning to become pregnant during the study period
  • Subjects who have experienced a medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)
  • Subjects who have known allergies to any in DA-002 or DA-005
  • Subjects who are currently participating in another clinical study or have completed another clinical study with an drug or device in the treatment area within 30 days prior to study treatment initiation
  • Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation
  • Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation
  • Subject is unable to provide consent or make the allotted clinical visits
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    DA-005

    Oral Botanical Supplement HIF-1a inhibitor

    Dietary Supplement: DA-005 · Other: Placebo Topical Solution

  • Active comparator
    Topical Minoxidil 5%

    Topical Minoxidil 5%

    Drug: Topical minoxidil 5% · Dietary Supplement: Placebo Oral Tablet

  • Experimental
    DA-002

    Topical Alpha 1 Agonist

    Drug: DA-002 · Dietary Supplement: Placebo Oral Tablet

Interventions

  • Dietary supplementDA-005

    Oral Botanical Supplement HIF-1a inhibitor

    Also known as: Daniel Alain Botanical Supplement Treatment for Hair Loss

  • DrugMinoxidilStudies of MinoxidilMinoxidil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Topical minoxidil 5%

  • DrugDA-002

    Topical Alpha 1 Agonist (GRAS)

  • Dietary supplementPlacebo Oral Tablet

    Placebo Oral Tablet

  • OtherPlacebo Topical Solution

    Placebo Topical Solution

06

What researchers measure

Primary outcomes

  1. Target Area Hair Counts

    Target Area Hair Counts

    Time frame: Week [0,12]

  2. Target Area Hair Counts

    Target Area Hair Counts

    Time frame: Week [0,24]

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Oct 2027, 9 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Jan 2025 → Jan 2027, primary completion Oct 2025 → Oct 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 15, 2024
StartEst.
Jan 15, 2027was Jan 2025
Primary completionEst.
Oct 17, 2027was Oct 2025
CompletionEst.
Dec 12, 2027was Dec 2025
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Sponsor change of formulation
changed Nov 2, 2026
Start date
Jan 15, 2025→Jan 15, 2027
Nov 2, 2026
Primary completion
Oct 17, 2025→Oct 17, 2027
Nov 2, 2026
Study completion
Dec 12, 2025→Dec 12, 2027
Nov 2, 2026
Enrollment
516 (estimated)→0 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Withdrawn
    Why stopped Sponsor change of formulation
    Start date Jan 15, 2025→Jan 15, 2027
    Primary completion Oct 17, 2025→Oct 17, 2027
    Study completion Dec 12, 2025→Dec 12, 2027
    Enrollment 516 (estimated)→0 (actual)
    + 6 other changes: identifiers, verification date, responsible party, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06501924
Collaborators
Follea International Limited, Daniel Alain, Inc.
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jan 15, 2027 (estimated)
Primary completion
Oct 17, 2027 (estimated)
Completion
Dec 12, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Andy Goren, MD
study director · University of Rome G. Marconi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion